Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C811 | ISIN: SE0016588867 | Ticker-Symbol: OL0
Frankfurt
24.04.25
15:29 Uhr
9,050 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
DEVYSER DIAGNOSTICS AB Chart 1 Jahr
5-Tage-Chart
DEVYSER DIAGNOSTICS AB 5-Tage-Chart
RealtimeGeldBriefZeit
8,6609,17008:14
GlobeNewswire (Europe)
76 Leser
Artikel bewerten:
(0)

Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser

Finanznachrichten News

Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.

Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally. He has led both listed companies and private Equity-owned companies. Jan most recently served as CEO at Mabtech.

"I am excited to join Devyser, a pioneer company in diagnostic kits for advanced DNA testing. I am looking forward to working alongside the great team at Devyser and continue to develop and sell world class products. I want to thank the board for the trust in me as we work towards continued successful growth.", says Jan Wahlström.

"Devyser's board and I are very pleased that Jan has agreed to lead Devyser," says the company's chair Mia Arnhult.

Devyser's previous CEO, Fredrik Alpsten, left the company in January and Fredrik Dahl, board member of Devyser, has since been acting CEO.

For more information, please contact:
Mia Arnhult, chair of the board
Telephone: +46 70-769 82 46

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.

© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.